4.54

1.52% -0.07

Coya Therapeutics Inc (COYA)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$4.61

Offen:

$4.55

24-Stunden-Volumen:

31,189

Relative Volume:

0.17

Marktkapitalisierung:

$106.73M

Einnahmen:

$7.94M

Nettoeinkommen (Verlust:

$-21.13M

KGV:

-4.1967

EPS:

-1.0818

Netto-Cashflow:

$-16.17M

1W Leistung:

+2.71%

1M Leistung:

-5.61%

6M Leistung:

-6.20%

1J Leistung:

-27.59%

1-Tages-Spanne:

$4.53

$4.695

1-Wochen-Bereich:

$4.36

$4.82

52-Wochen-Spanne:

$3.7101

$7.75

Coya Therapeutics Inc Stock (COYA) Company Profile

Firmenname

Coya Therapeutics Inc

Sektor

Healthcare (1087)

Branche

Biotechnology (606)

Telefon

650.739.3939

Adresse

12645 MEMORIAL DR., SUITE F1 #305, HOUSTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-11

Neueste SEC-Einreichungen

COYA's Discussions on Twitter

Compare COYA vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
COYA Coya Therapeutics Inc	4.55	108.14M	7.94M	-21.13M	-16.17M	-1.0818
VRTX Vertex Pharmaceuticals Inc	522.72	134.06B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	804.34	83.43B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,003.96	63.00B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.64	56.02B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.05	44.44B	742.00K	-1.37B	-1.07B	-7.0731

Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-09	Eingeleitet	Lake Street	Buy
2024-12-04	Eingeleitet	D. Boral Capital	Buy

Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten

Sep 08, 2026

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation - BioSpace

Sep 08, 2026

Sep 07, 2026

$32 Million Exosome Therapy Market Assessment 2026: Set to Experience Massive Growth, Reaching $1.4 Billion by 2040 - GlobeNewswire Inc.

Sep 07, 2026

Sep 01, 2026

COYA: Treg-based combination therapies show promise in ALS and FTD, with key data expected in 2027 - TradingView

Sep 01, 2026

Aug 26, 2026

Coya Therapeutics Advances Phase 2 ALSTARS ALS Trial Toward 2026 Enrollment Finish - Streetwise Reports

Aug 26, 2026

Aug 25, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Aug 25, 2026

Is This Biopharmaceutical Co. Developing ALS Drug a Buy? - Streetwise Reports

Aug 25, 2026

Aug 24, 2026

H.C. Wainwright reiterates Coya Therapeutics stock rating at buy By Investing.com - Investing.com UK

Aug 24, 2026

Aug 21, 2026

Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Aug 21, 2026

Aug 14, 2026

COYA|Coya Therapeutics Inc|Price:4.790|Chg%:+0.120 - TradingKey

Aug 14, 2026

Aug 13, 2026

Coya Therapeutics (COYA) Holds Ground at $4.67 as Consolidation ContinuesOBV Divergence - vinanet.vn

Aug 13, 2026

Experimental ALS treatment being tested in Philadelphia: "There's potential here for a home run" - CBS News

Aug 13, 2026

Coya Therapeutics (COYA) Edges Up 0.85% to $4.73, Holding Support Amid ConsolidationGEX Level - vinanet.vn

Aug 13, 2026

COYA Q1 2026 Earnings: Narrower-Than-Expected Loss Offers a Favorable SurpriseNext Quarter Guidance - vinanet.vn

Aug 13, 2026

COYA Pulls Back to $4.69: Coya Therapeutics Approaches Critical Support LevelHigh Dividend Factor - vinanet.vn

Aug 13, 2026

Aug 12, 2026

Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat

Aug 12, 2026